(CA Technologies, Inc., Islandia, NY, www.ca.com) The world's largest diversified software vendor offering more than 500 applications from micro to mainframe. Founded as Computer Associates in 1976 by Charles Wang and three associates, its first product was CA-SORT, a very successful IBM mainframe utility. Its first personal computer software was SuperCalc, one of the earliest spreadsheets. CA Technologies grew via numerous acquisitions over the years, and in 1989, was the first independent software company to reach $1 billion in sales. In 2018, CA was acquired by Broadcom and operates as a Broadcom subsidiary.
Charles Wang Wang developed the world's largest diversified software company that covers all segments of the industry from micro to mainframe. (Image courtesy of CA Technologies, Inc., www.ca.com)Dedrone has named Ben Wenger, a two-decade enterprise software sales veteran, as chief revenue officer and appointed Mary-Lou Smulders, strategic
Michael Barnes, former senior strategic account executive for the Department of Agriculture at Salesforce (NYSE: CRM), has joined Google's (Nasdaq:…
Mark Fabian, former strategic account executive at CA Technologies' federal business, has joined The Ambit Group as vice president of growth,…
According to this latest study, In 2022 the growth of ITSM Software Market is projected to reach Multimillion USD by 2028, In comparison to 2021, Over the next Seven years the ITSM Software Market will register a spectacular spike in CAGR in terms of revenue, In this study, 2021 has been considered as the base year and 2022 to 2028 as the forecast period to estimate the market size for ITSM Software.
“ITSM Software Market” Insights 2022 By Types, Applications, Regions and Forecast to 2028. The global ITSM Software market size is projected to Reach Multimillion USD by 2028, in comparison to 2022, with unexpected CAGR during the forecast period, the ITSM Software Market Report Contains Full TOC, Tables and Figures, and Chart with In-depth Analysis Pre and Post COVID-19 Market Outbreak Impact Analysis and Situation by Region.
ITSM Software Market – Covid-19 Impact and Recovery Analysis:
We have been tracking the direct impact of COVID-19 on this market, as well as the indirect impact from other industries. This report analyzes the impact of the pandemic on the ITSM Software market from a Global and Regional perspective. The report outlines the market size, market characteristics, and market growth for ITSM Software industry, categorized by type, application, and consumer sector. In addition, it provides a comprehensive analysis of aspects involved in market development before and after the Covid-19 pandemic. Report also conducted a PESTEL analysis in the industry to study key influencers and barriers to entry.
Final Report will add the analysis of the impact of COVID-19 on this industry.
TO UNDERSTAND HOW COVID-19 IMPACT IS COVERED IN THIS REPORT – REQUEST SAMPLE
It also provides accurate information and cutting-edge analysis that is necessary to formulate an ideal business plan, and to define the right path for rapid growth for all involved industry players. With this information, stakeholders will be more capable of developing new strategies, which focus on market opportunities that will benefit them, making their business endeavours profitable in the process.
Get a demo PDF of report –https://www.360researchreports.com/enquiry/request-sample/17526533
ITSM Software Market – Competitive and Segmentation Analysis:
This ITSM Software Market report offers detailed analysis supported by reliable statistics on sale and revenue by players for the period 2017-2022. The report also includes company description, major business, ITSM Software product introduction, accurate developments and ITSM Software sales by region, type, application and by sales channel.
The major players covered in the ITSM Software market report are:
- Atlassian
- ASG Technologies
- CA Technologies
- Microsoft
- BMC Software, Inc.
- IBM
- LogMeIn, Inc.
- ServiceNow
- SolarWinds
- Ivanti
Short Summery About ITSM Software Market :
The Global ITSM Software market is anticipated to rise at a considerable rate during the forecast period, between 2022 and 2028. In 2021, the market is growing at a steady rate and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.
Highlights
The global ITSM Software market is projected to reach USD million by 2028 from an estimated USD million in 2022, at a magnificent CAGR during 2023 and 2028.
North American market for ITSM Software is estimated to increase from USD million in 2022 to reach USD million by 2028, at a Impressive CAGR during the forecast period of 2023 through 2028.
Asia-Pacific market for ITSM Software is estimated to increase from USD million in 2022 to reach USD million by 2028, at a magnificent CAGR during the forecast period of 2022 through 2028.
The global market for ITSM Software in Wired Telephone Network System is estimated to increase from USD million in 2022 to USD million by 2028, at a Impressive CAGR during the forecast period of 2022 through 2028.
Considering the economic change due to COVID-19 and Russia-Ukraine War Influence, ITSM Software, which accounted for % of the global market of ITSM Software in 2021, is expected to reach million USD by 2028, growing at a revised CAGR of % from 2022 to 2028.
Report Scope
This report aims to provide a comprehensive presentation of the global market for ITSM Software, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding ITSM Software.
The ITSM Software market size, estimations, and forecasts are provided in terms of output/shipments (K Units) and revenue (USD millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global ITSM Software market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the ITSM Software manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, production, and average price for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Key Companies and Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Get a demo Copy of the ITSM Software Market Report 2022
Report further studies the market development status and future ITSM Software Market trend across the world. Also, it splits ITSM Software market Segmentation by Type and by Applications to fully and deeply research and reveal market profile and prospects.
On the basis of product type this report displays the production, revenue, price, market share and growth rate of each type, primarily split into:
On the basis of the end users/applications this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including:
- Small and Medium Enterprises (SMEs)
- Large Enterprises
ITSM Software Market – Regional Analysis:
Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth Rate of ITSM Software in these regions, from 2015 to 2027, covering
- North America (United States, Canada and Mexico)
- Europe (Germany, UK, France, Italy, Russia and Turkey etc.)
- Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
- South America (Brazil, Argentina, Columbia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Some of the key questions answered in this report:
- What is the global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) sales value, production value, consumption value, import and export of ITSM Software?
- Who are the global key manufacturers of the ITSM Software Industry? How is their operating situation (capacity, production, sales, price, cost, gross, and revenue)?
- What are the ITSM Software market opportunities and threats faced by the vendors in the global ITSM Software Industry?
- Which application/end-user or product type may seek incremental growth prospects? What is the market share of each type and application?
- What focused approach and constraints are holding the ITSM Software market?
- What are the different sales, marketing, and distribution channels in the global industry?
- What are the upstream raw materials and manufacturing equipment of ITSM Software along with the manufacturing process of ITSM Software?
- What are the key market trends impacting the growth of the ITSM Software market?
- Economic impact on the ITSM Software industry and development trend of the ITSM Software industry.
- What are the market opportunities, market risk, and market overview of the ITSM Software market?
- What are the key drivers, restraints, opportunities, and challenges of the ITSM Software market, and how they are expected to impact the market?
- What is the ITSM Software market size at the regional and country-level?
Our research analysts will help you to get customized details for your report, which can be modified in terms of a specific region, application or any statistical details. In addition, we are always willing to comply with the study, which triangulated with your own data to make the market research more comprehensive in your perspective.
Inquire more and share questions if any before the purchase on this report at –https://www.360researchreports.com/enquiry/pre-order-enquiry/17526533
Detailed TOC of Global ITSM Software Market Research Report 2022
1 ITSM Software Market Overview
1.1 Product Overview and Scope of ITSM Software
1.2 ITSM Software Segment by Type
1.2.1 Global ITSM Software Market Size Growth Rate Analysis by Type 2022 VS 2028
1.3 ITSM Software Segment by Application
1.3.1 Global ITSM Software Consumption Comparison by Application: 2022 VS 2028
1.4 Global Market Growth Prospects
1.4.1 Global ITSM Software Revenue Estimates and Forecasts (2017-2028)
1.4.2 Global ITSM Software Production Capacity Estimates and Forecasts (2017-2028)
1.4.3 Global ITSM Software Production Estimates and Forecasts (2017-2028)
1.5 Global Market Size by Region
1.5.1 Global ITSM Software Market Size Estimates and Forecasts by Region: 2017 VS 2021 VS 2028
1.5.2 North America ITSM Software Estimates and Forecasts (2017-2028)
1.5.3 Europe ITSM Software Estimates and Forecasts (2017-2028)
1.5.4 China ITSM Software Estimates and Forecasts (2017-2028)
1.5.5 Japan ITSM Software Estimates and Forecasts (2017-2028)
2 Market Competition by Manufacturers
2.1 Global ITSM Software Production Capacity Market Share by Manufacturers (2017-2022)
2.2 Global ITSM Software Revenue Market Share by Manufacturers (2017-2022)
2.3 ITSM Software Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.4 Global ITSM Software Average Price by Manufacturers (2017-2022)
2.5 Manufacturers ITSM Software Production Sites, Area Served, Product Types
2.6 ITSM Software Market Competitive Situation and Trends
2.6.1 ITSM Software Market Concentration Rate
2.6.2 Global 5 and 10 Largest ITSM Software Players Market Share by Revenue
2.6.3 Mergers and Acquisitions, Expansion
3 Production Capacity by Region
3.1 Global Production Capacity of ITSM Software Market Share by Region (2017-2022)
3.2 Global ITSM Software Revenue Market Share by Region (2017-2022)
3.3 Global ITSM Software Production Capacity, Revenue, Price and Gross Margin (2017-2022)
3.4 North America ITSM Software Production
3.4.1 North America ITSM Software Production Growth Rate (2017-2022)
3.4.2 North America ITSM Software Production Capacity, Revenue, Price and Gross Margin (2017-2022)
3.5 Europe ITSM Software Production
3.5.1 Europe ITSM Software Production Growth Rate (2017-2022)
3.5.2 Europe ITSM Software Production Capacity, Revenue, Price and Gross Margin (2017-2022)
3.6 China ITSM Software Production
3.6.1 China ITSM Software Production Growth Rate (2017-2022)
3.6.2 China ITSM Software Production Capacity, Revenue, Price and Gross Margin (2017-2022)
3.7 Japan ITSM Software Production
3.7.1 Japan ITSM Software Production Growth Rate (2017-2022)
3.7.2 Japan ITSM Software Production Capacity, Revenue, Price and Gross Margin (2017-2022)
4 Global ITSM Software Consumption by Region
4.1 Global ITSM Software Consumption by Region
4.1.1 Global ITSM Software Consumption by Region
4.1.2 Global ITSM Software Consumption Market Share by Region
4.2 North America
4.2.1 North America ITSM Software Consumption by Country
4.2.2 United States
4.2.3 Canada
4.3 Europe
4.3.1 Europe ITSM Software Consumption by Country
4.3.2 Germany
4.3.3 France
4.3.4 U.K.
4.3.5 Italy
4.3.6 Russia
4.4 Asia Pacific
4.4.1 Asia Pacific ITSM Software Consumption by Region
4.4.2 China
4.4.3 Japan
4.4.4 South Korea
4.4.5 China Taiwan
4.4.6 Southeast Asia
4.4.7 India
4.4.8 Australia
4.5 Latin America
4.5.1 Latin America ITSM Software Consumption by Country
4.5.2 Mexico
4.5.3 Brazil
Get a demo Copy of the ITSM Software Market Report 2022
5 Segment by Type
5.1 Global ITSM Software Production Market Share by Type (2017-2022)
5.2 Global ITSM Software Revenue Market Share by Type (2017-2022)
5.3 Global ITSM Software Price by Type (2017-2022)
6 Segment by Application
6.1 Global ITSM Software Production Market Share by Application (2017-2022)
6.2 Global ITSM Software Revenue Market Share by Application (2017-2022)
6.3 Global ITSM Software Price by Application (2017-2022)
7 Key Companies Profiled
7.1 Company
7.1.1 ITSM Software Corporation Information
7.1.2 ITSM Software Product Portfolio
7.1. CITSM Software Production Capacity, Revenue, Price and Gross Margin (2017-2022)
7.1.4 Company’s Main Business and Markets Served
7.1.5 Company’s accurate Developments/Updates
8 ITSM Software Manufacturing Cost Analysis
8.1 ITSM Software Key Raw Materials Analysis
8.1.1 Key Raw Materials
8.1.2 Key Suppliers of Raw Materials
8.2 Proportion of Manufacturing Cost Structure
8.3 Manufacturing Process Analysis of ITSM Software
8.4 ITSM Software Industrial Chain Analysis
9 Marketing Channel, Distributors and Customers
9.1 Marketing Channel
9.2 ITSM Software Distributors List
9.3 ITSM Software Customers
10 Market Dynamics
10.1 ITSM Software Industry Trends
10.2 ITSM Software Market Drivers
10.3 ITSM Software Market Challenges
10.4 ITSM Software Market Restraints
11 Production and Supply Forecast
11.1 Global Forecasted Production of ITSM Software by Region (2023-2028)
11.2 North America ITSM Software Production, Revenue Forecast (2023-2028)
11.3 Europe ITSM Software Production, Revenue Forecast (2023-2028)
11.4 China ITSM Software Production, Revenue Forecast (2023-2028)
11.5 Japan ITSM Software Production, Revenue Forecast (2023-2028)
12 Consumption and Demand Forecast
12.1 Global Forecasted Demand Analysis of ITSM Software
12.2 North America Forecasted Consumption of ITSM Software by Country
12.3 Europe Market Forecasted Consumption of ITSM Software by Country
12.4 Asia Pacific Market Forecasted Consumption of ITSM Software by Region
12.5 Latin America Forecasted Consumption of ITSM Software by Country
13 Forecast by Type and by Application (2023-2028)
13.1 Global Production, Revenue and Price Forecast by Type (2023-2028)
13.1.1 Global Forecasted Production of ITSM Software by Type (2023-2028)
13.1.2 Global Forecasted Revenue of ITSM Software by Type (2023-2028)
13.1.3 Global Forecasted Price of ITSM Software by Type (2023-2028)
13.2 Global Forecasted Consumption of ITSM Software by Application (2023-2028)
13.2.1 Global Forecasted Production of ITSM Software by Application (2023-2028)
13.2.2 Global Forecasted Revenue of ITSM Software by Application (2023-2028)
13.2.3 Global Forecasted Price of ITSM Software by Application (2023-2028)
14 Research Finding and Conclusion
15 Methodology and Data Source
15.1 Methodology/Research Approach
15.1.1 Research Programs/Design
15.1.2 Market Size Estimation
15.1.3 Market Breakdown and Data Triangulation
15.2 Data Source
15.2.1 Secondary Sources
15.2.2 Primary Sources
15.3 Author List
15.4 Disclaimer
Continued….
Purchase this report (Price 3360 USD for a single-user license) –https://www.360researchreports.com/purchase/17526533
About Us:
360 Research Reports is the credible source for gaining the market reports that will provide you with the lead your business needs. At 360 Research Reports, our objective is providing a platform for many top-notch market research firms worldwide to publish their research reports, as well as helping the decision makers in finding most suitable market research solutions under one roof. Our aim is to provide the best solution that matches the exact customer requirements. This drives us to provide you with custom or syndicated research reports.
Contact Us:
Web https://360researchreports.com
Email: [email protected]
Organization: 360 Research Reports
Phone: +44 20 3239 8187/ +14242530807
Our Other Reports :
Paper and Paperboard Container and Packaging Market
Computerized Numerical Control (CNC) Market
Press Release Distributed by The Express Wire
To view the original version on The Express Wire visit ITSM Software Market Study Providing Information on Top Key Players | Atlassian, ASG Technologies, CA Technologies, Microsoft And More
Campaign to Create Tomorrow
Learn more about The Ottawa Hospital's $500-million fundraising campaign, the largest in our city’s history, which will transform the future of healthcare in Ottawa.
A new analysis from the Center for Legislative Accountability (CLA) solidifies conservatives’ growing isolation in the State of California.
The analysis from CLA, a project of CPA and the American Conservation Union Foundation, says California lawmakers are trending even more progressive, dropping the Golden State three spots – from #44 to #47 – since the last results.
FILE: California state Capitol for file art. Photographed at state Capitol on Sunday, July 17, 2022 in Sacramento, CA. (Myung J. Chun / Los Angeles Times via Getty Images)
CLA’s studied all 7,400 state lawmakers across America by voting record and gave the California legislature a conservative rating of 24%. Only Rhode Island, at 20%, Hawaii, at 19%, and Massachusetts, at 15%, are more liberal than California.
Lawmakers’ "conservative rating" were calculated by their voting record across 186 policy areas that ranged from cultural and life issues, to tax, fiscal, and other regulations, CPAC says.
NEWSOM WON'T CHALLENGE BIDEN IN 2024, SAYS HE IS ‘ALL IN’ ON PRESIDENT'S RE-ELECTION
CLA tallied more than 320,000 votes each to generate the scores and 50 state rankings. Only 17 California Republican lawmakers earned awards from CPAC for holding a conservative rating of 80% or more.
In California, Democratic state senators outnumber Republicans 29 to 9. Democratic assembly members outnumber Republicans 58 to 17.
CLICK HERE TO GET THE FOX NEWS APP
The study projected that the November midterms will only worsen the plunge after the projected flip of Republican seats to Democrat in the state Assembly.
As It Happens6:30Swearing feels good — and research suggests it's good for you, too
Taking notes while someone holds their hand in freezing cold water and hurls profanities may seem like an odd way to spend an afternoon, but for Richard Stephens, it's just another day at the office.
Stephens and his colleagues study the psychological effects of swearing. And according to their accurate review of available research on the topic, swearing helps people tolerate pain, ease stress, build and maintain interpersonal connections, and in some cases, be more persuasive.
"I think [these studies are] really kind of putting a scientific stamp on what most people know anyway," Stephens, a psychologist and lecturer at Keele University in England, told As It Happens host Nil Köksal.
"People know if they hurt themselves, it's a good idea to swear because it seems to help. People know it helps express frustration."
Stephens and his colleagues reviewed 100 academic papers from different disciplines about the consequences of cussing, including their own research. Their findings were published in the journal Lingua.
Cursing to make friends and influence people
Several studies over the years have highlighted the social benefits of swearing. They found it can build a sense of camaraderie and solidarity within a group, especially if that group faces adversity or outside opposition.
Other studies have suggested that swearing can help create a sense of trust and intimacy among co-workers, sports teams and friend groups.
It's even effective at forging "parasocial" relationships — one-sided bonds where a person feels close to someone they don't actually know, usually a celebrity or an influencer — according to a 2017 analysis of controversial YouTuber PewDiePie.
Stephens says swearing's social power stems from the fact that it's frowned upon in many professional and social settings. Cursing, therefore, can feel very intimate and authentic.
"The idea is that if someone is speaking and they're swearing, that they're speaking in an unfiltered way," he said. "They're not managing how they look or sound to other people. And so, you know, theoretically, that should make you think, well, they're being honest."
In some cases, Stephens said, this even helps people to be more persuasive — with some caveats.
"It does seem to depend on what your initial beliefs are, because if you strongly disagree with someone and they start swearing, that gives you a reason to carry on strongly disagreeing. It gives you a reason to dislike them," he said. "So it is a bit nuanced, that one."
The healing power of a potty mouth
But it's not all social. Some of swearing's power is deeply personal. For example, Stephens says it's a tremendous tool for pain management.
This is Stephens' area of expertise. He and his colleagues have published several studies about swearing and pain.
Most recently, their 2020 study found people can hold their hand in freezing cold water longer if they're repeating a swear word. Repeating a neutral word didn't have the same effect.
"So swearing seems to help people cope with pain," he said.
In that study, participants used a swear word of their own choice, Stephens said, because "swearing is quite a personal thing."
That might explain why several studies have found that swearing has a bigger emotional impact when you do it in your first language.
"When people swear in a second or third language, it just doesn't seem to have the same power or emotional impact, whatever you want to call it, as swearing in the mother tongue," Stephens said.
Excessive expletives exempted
Stephens says he has some as-yet unpublished research to suggest that the intensity of the swear word matters too. People are better able to tolerate pain while dropping F-bombs, he says, than something less vulgar, like "bum."
"It does seem to be that the stronger the swear word, the more effect it has," he said.
But he has a warning for those known to swear like a sailor: Swearing's power has diminishing returns.
"We found that the people who swear the most in everyday life got the least benefit from swearing," he said. "So, you know, don't overdo it."
This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021.
MONTREAL, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has decided to pause the enrollment of patients in its Phase 1 clinical trial of TH1902, the Company’s lead investigational peptide drug conjugate (PDC) for the treatment of sortilin-expressing cancers. The Company plans to submit an amendment to its protocol to the U.S. Food and Drug Administration (FDA) for approval.
Theratechnologies voluntarily made the decision to pause enrollment and revisit the study design after consulting with its investigators. Efficacy results observed thus far were not convincing enough to pursue enrolling patients and did not outweigh the adverse events seen in some patients. As previously reported, these adverse events consist mainly of neuropathy and eye toxicity.
The current intent for the protocol amendment is to modify the dosage regimen to optimize the delivery of TH1902, with lower doses at more frequent intervals. The Company continues to investigate the results obtained thus far in the Phase 1 clinical trial.
“While we are disappointed with these developments, we remain committed to advancing our SORT1+ Technology platform and will continue investigating its potential in the treatment of advanced cancers,” said Christian Marsolais, Ph.D., Senior Vice President and Chief Medical Officer, Theratechnologies.
About SORT1+ Technology™ and TH1902
Theratechnologies is currently developing a platform of proprietary peptides called SORT1+ TechnologyTM for cancer drug development targeting SORT1 receptors. The SORT1 receptor plays a significant role in protein internalization, sorting and trafficking. It is highly expressed in cancer cells compared to healthy tissue, which makes SORT1 an attractive target for cancer drug development. Expression of SORT1 is associated with aggressive disease, poor prognosis and decreased survival. It is estimated that the SORT1 receptor is expressed in 40% to 90% of cases of endometrial, ovarian, colorectal, triple-negative breast and pancreatic cancers.
TH1902 is currently Theratechnologies’ lead investigational PDC candidate for the treatment of cancer derived from its SORT1+ Technology™. It is the Company’s proprietary peptide linked to docetaxel – a commonly used cytotoxic agent used to treat many cancers. The FDA granted fast track designation to TH1902 as a single agent for the treatment of all sortilin-positive recurrent advanced solid tumors that are refractory to standard therapy.
About Theratechnologies
Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR at www.sedar.com and on EDGAR at www.sec.gov.
Forward-Looking Information
This press release contains forward-looking statements and forward-looking information (collectively, “Forward-Looking Statements”), within the meaning of applicable securities laws, that are based on our management’s beliefs and assumptions and on information currently available to our management. You can identify Forward-Looking Statements by terms such as "may", "will", "should", "could", “would”, "outlook", "believe", "plan", "envisage", "anticipate", "expect" and "estimate", or the negatives of these terms, or variations of them. The Forward-Looking Statements contained in this press release include, but are not limited to, statements regarding the filing of an amendment to its Phase 1 clinical trial protocol to the FDA, the optimization of the dosage regimen of TH1902 and the advancement of the SORT1+ TechnologyTM platform. Although the Forward-Looking Statements contained in this press release are based upon what the Company believes are reasonable assumptions in light of the information currently available, investors are cautioned against placing undue reliance on these statements since actual results may vary from the Forward-Looking Statements. Certain assumptions made in preparing the Forward-Looking Statements include that the amendments to the protocol to be submitted to the FDA will be approved by the FDA allowing the Company to pursue its Phase 1 clinical trial using TH1902, the proposed revised dosage regimen will generate results similar to those observed in preclinical model, research and development work on the SORT1+ TechnologyTM platform will yield positive results leading to the development of one or many drugs treating various types of cancer. Forward-Looking Statements assumptions are subject to a number of risks and uncertainties, many of which are beyond Theratechnologies’ control that could cause actual results to differ materially from those that are disclosed in or implied by such Forward-Looking Statements. These risks and uncertainties include, but are not limited to, the non-approval by the FDA of the amendments to the protocol of the Phase 1 clinical trial studying TH1902, the halt of the Phase 1 clinical trial using TH1902, the observation of adverse safety issues and the lack of demonstration of efficacy in many or in all of the patients forming part of the Phase 1 clinical trial, difficulty in recruiting patients if we resume the clinical trial, and lack of resources to further develop the SORT1+ TechnologyTM platform. We refer current and potential investors to the “Risk Factors” section of our Annual Information Form dated February 23, 2022 available on SEDAR at www.sedar.com and on EDGAR at www.sec.gov as an exhibit to our report on Form 40-F dated February 24, 2022 under Theratechnologies’ public filings for additional risks related to the Company. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on Forward-Looking Statements. Forward-Looking Statements reflect current expectations regarding future events and speak only as of the date of this press release and represent our expectations as of that date. We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise, except as may be required by applicable law.
Contacts:
Investor inquiries:
Elif McDonald
Senior Director, Investor Relations
ir@theratech.com
1-438-315-8563
Media inquiries:
Julie Schneiderman
Senior Director, Communications & Corporate Affairs
communications@theratech.com
1-514-336-7800
Key Financial Results
-
Revenue: CA$7.89m (up 49% from FY 2021).
-
Net income: CA$1.67m (up 120% from FY 2021).
-
Profit margin: 21% (up from 14% in FY 2021). The increase in margin was driven by higher revenue.
-
EPS: CA$0.067 (up from CA$0.031 in FY 2021).
All figures shown in the chart above are for the trailing 12 month (TTM) period
IBEX Technologies shares are down 15% from a week ago.
Risk Analysis
Be aware that IBEX Technologies is showing 2 warning signs in our investment analysis that you should know about...
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here
PORTLAND, Tenn., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Shoals Technologies Group, Inc. (Nasdaq: SHLS) (the “Company”) today announced the pricing of its upsized underwritten public offering of an aggregate of 26,000,000 shares of the Company’s Class A common stock, at a price to the public of $22.25 per share. The Company is offering 2,000,000 shares of its Class A common stock, and certain selling stockholders (collectively, the “Selling Stockholders”), comprising Dean Solon and certain of his affiliates, are offering 24,000,000 shares of the Company’s Class A common stock.
As previously announced, on November 29, 2022, the Company entered into an amendment to its Tax Receivable Agreement, pursuant to which the parties thereto agreed to grant the Company a right to terminate the Tax Receivable Agreement until December 31, 2022 (the “TRA Termination Right”) in exchange for a termination consideration of $58.1 million payable in cash (the “TRA Termination Consideration”).
The Company has exercised its TRA Termination Right, subject to the consummation of this offering. The Company intends to use the net proceeds from the offering to fund a portion of the TRA Termination Consideration, with the remainder to be paid with cash on hand. The Company will not receive any of the proceeds from the sale of Class A common stock offered by the Selling Stockholders.
The Selling Stockholders also granted the underwriters a 30-day option to purchase up to an additional 3,900,000 shares of Class A common stock. The Company’s Class A common stock is listed on the Nasdaq Global Market under the symbol “SHLS.” The offering is expected to close on December 6, 2022, subject to customary closing conditions.
J.P. Morgan Securities LLC, Guggenheim Securities, LLC and Morgan Stanley are acting as joint book-running managers for the offering. UBS Investment Bank is also acting as a joint book-running manager and Goldman Sachs & Co. LLC, Barclays and Credit Suisse are also acting as book-runners. Cowen, Oppenheimer & Co. Inc., Piper Sandler, Roth Capital Partners, Johnson Rice & Company L.L.C. and Northland Capital Markets are acting as co-managers.
The shares of Class A common stock in this offering are being offered pursuant to an automatically effective shelf registration statement on Form S-3 filed with the Securities and Exchange Commission (“SEC”) on November 30, 2022. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering was filed with the SEC and is available on the SEC’s website at www.sec.gov. The final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and may be obtained, when available, from: J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 (telephone: 1-866-803-9204), or by email at prospectus-eq_fi@jpmchase.com; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison, 8th Floor, New York, NY 10017, by telephone at (212) 518-9658, or by email at GSEquityProspectusDelivery@guggenheimpartners.com; and Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, Second Floor, New York, New York 10014; or by accessing the SEC’s website at www.sec.gov.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Shoals Technologies Group, Inc.
Shoals Technologies Group, Inc. is a leading provider of electrical balance of system solutions and components for solar, battery storage and electric vehicle charging applications, selling to customers across the United States and internationally. Since its founding in 1996, the Company has introduced innovative technologies and systems solutions that allow its customers to substantially increase installation efficiency and safety while improving system performance and reliability. Shoals Technologies Group, Inc. is a recognized leader in the renewable energy industry whose solutions are deployed on over 20 GW of solar systems globally.
Forward-Looking Statements
This press release contains forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available to our management. Forward-looking statements include information concerning our possible or assumed future results of operations, business strategies, technology developments, financing and investment plans, dividend policy, competitive position, industry and regulatory environment, potential growth opportunities and the effects of competition. Forward-looking statements include statements that are not historical facts and can be identified by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “will,” “would” or similar expressions and the negatives of those terms.
Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include changes to Mr. Whitaker’s circumstances, inability to find a new CEO, the impact of the announcement of the succession on the Company’s stock and its employees, suppliers and customers, and other risks and uncertainties described in the Company’s most accurate Annual Report on Form 10-K and subsequent filings with the Securities and Exchange Commission. Given these uncertainties, you should not place undue reliance on forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date of this report. You should read this press release with the understanding that our actual future results may be materially different from what we expect.
Except as required by law, we assume no obligation to update these forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
Contacts
Investors:
Email: investors@shoals.com
Media:
Email: media@shoals.com
This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021.
MONTREAL, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has decided to pause the enrollment of patients in its Phase 1 clinical trial of TH1902, the Company’s lead investigational peptide drug conjugate (PDC) for the treatment of sortilin-expressing cancers. The Company plans to submit an amendment to its protocol to the U.S. Food and Drug Administration (FDA) for approval.
Theratechnologies voluntarily made the decision to pause enrollment and revisit the study design after consulting with its investigators. Efficacy results observed thus far were not convincing enough to pursue enrolling patients and did not outweigh the adverse events seen in some patients. As previously reported, these adverse events consist mainly of neuropathy and eye toxicity.
The current intent for the protocol amendment is to modify the dosage regimen to optimize the delivery of TH1902, with lower doses at more frequent intervals. The Company continues to investigate the results obtained thus far in the Phase 1 clinical trial.
“While we are disappointed with these developments, we remain committed to advancing our SORT1+ Technology platform and will continue investigating its potential in the treatment of advanced cancers,” said Christian Marsolais, Ph.D., Senior Vice President and Chief Medical Officer, Theratechnologies.
About SORT1+ Technology™ and TH1902
Theratechnologies is currently developing a platform of proprietary peptides called SORT1+ TechnologyTM for cancer drug development targeting SORT1 receptors. The SORT1 receptor plays a significant role in protein internalization, sorting and trafficking. It is highly expressed in cancer cells compared to healthy tissue, which makes SORT1 an attractive target for cancer drug development. Expression of SORT1 is associated with aggressive disease, poor prognosis and decreased survival. It is estimated that the SORT1 receptor is expressed in 40% to 90% of cases of endometrial, ovarian, colorectal, triple-negative breast and pancreatic cancers.
TH1902 is currently Theratechnologies’ lead investigational PDC candidate for the treatment of cancer derived from its SORT1+ Technology™. It is the Company’s proprietary peptide linked to docetaxel – a commonly used cytotoxic agent used to treat many cancers. The FDA granted fast track designation to TH1902 as a single agent for the treatment of all sortilin-positive recurrent advanced solid tumors that are refractory to standard therapy.
About Theratechnologies
Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR at www.sedar.com and on EDGAR at www.sec.gov.
Forward-Looking Information
This press release contains forward-looking statements and forward-looking information (collectively, “Forward-Looking Statements”), within the meaning of applicable securities laws, that are based on our management’s beliefs and assumptions and on information currently available to our management. You can identify Forward-Looking Statements by terms such as "may", "will", "should", "could", “would”, "outlook", "believe", "plan", "envisage", "anticipate", "expect" and "estimate", or the negatives of these terms, or variations of them. The Forward-Looking Statements contained in this press release include, but are not limited to, statements regarding the filing of an amendment to its Phase 1 clinical trial protocol to the FDA, the optimization of the dosage regimen of TH1902 and the advancement of the SORT1+ TechnologyTM platform. Although the Forward-Looking Statements contained in this press release are based upon what the Company believes are reasonable assumptions in light of the information currently available, investors are cautioned against placing undue reliance on these statements since actual results may vary from the Forward-Looking Statements. Certain assumptions made in preparing the Forward-Looking Statements include that the amendments to the protocol to be submitted to the FDA will be approved by the FDA allowing the Company to pursue its Phase 1 clinical trial using TH1902, the proposed revised dosage regimen will generate results similar to those observed in preclinical model, research and development work on the SORT1+ TechnologyTM platform will yield positive results leading to the development of one or many drugs treating various types of cancer. Forward-Looking Statements assumptions are subject to a number of risks and uncertainties, many of which are beyond Theratechnologies’ control that could cause actual results to differ materially from those that are disclosed in or implied by such Forward-Looking Statements. These risks and uncertainties include, but are not limited to, the non-approval by the FDA of the amendments to the protocol of the Phase 1 clinical trial studying TH1902, the halt of the Phase 1 clinical trial using TH1902, the observation of adverse safety issues and the lack of demonstration of efficacy in many or in all of the patients forming part of the Phase 1 clinical trial, difficulty in recruiting patients if we resume the clinical trial, and lack of resources to further develop the SORT1+ TechnologyTM platform. We refer current and potential investors to the “Risk Factors” section of our Annual Information Form dated February 23, 2022 available on SEDAR at www.sedar.com and on EDGAR at www.sec.gov as an exhibit to our report on Form 40-F dated February 24, 2022 under Theratechnologies’ public filings for additional risks related to the Company. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on Forward-Looking Statements. Forward-Looking Statements reflect current expectations regarding future events and speak only as of the date of this press release and represent our expectations as of that date. We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise, except as may be required by applicable law.
Contacts:
Investor inquiries:
Elif McDonald
Senior Director, Investor Relations
ir@theratech.com
1-438-315-8563
Media inquiries:
Julie Schneiderman
Senior Director, Communications & Corporate Affairs
communications@theratech.com
1-514-336-7800
